1. Home
  2. NATL vs CELC Comparison

NATL vs CELC Comparison

Compare NATL & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCR Atleos Corporation

NATL

NCR Atleos Corporation

HOLD

Current Price

$37.74

Market Cap

2.7B

Sector

N/A

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$102.99

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NATL
CELC
Founded
2023
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NATL
CELC
Price
$37.74
$102.99
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$42.75
$100.13
AVG Volume (30 Days)
446.1K
955.3K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.74
N/A
Revenue
$4,322,000,000.00
N/A
Revenue This Year
$2.83
N/A
Revenue Next Year
$3.96
N/A
P/E Ratio
$21.33
N/A
Revenue Growth
0.63
N/A
52 Week Low
$22.30
$7.58
52 Week High
$42.23
$108.91

Technical Indicators

Market Signals
Indicator
NATL
CELC
Relative Strength Index (RSI) 57.85 70.63
Support Level $36.12 $96.70
Resistance Level $37.61 $108.91
Average True Range (ATR) 1.02 5.09
MACD 0.21 -0.64
Stochastic Oscillator 95.11 65.62

Price Performance

Historical Comparison
NATL
CELC

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: